Navigation Links
Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
Date:7/10/2008

ntibody with enhanced antibody effector function that targets CD70, a member of the TNF family that is highly expressed on multiple cancers, including renal cell carcinoma, lymphoma and glioblastoma. CD70 expression on activated lymphocytes may also be implicated in autoimmune diseases. Data from the ongoing Phase 1 trial in clear cell renal carcinoma is expected in 2009. Additional opportunities include the expected initiation of a Phase 1 trial of MDX-1411 in lymphomas in 2008, as well as an anti-CD70 antibody-drug conjugate program.

-- MDX-1203 targets the CD70 molecule expressed on multiple cancers and is expected to be the first Medarex antibody-drug conjugate candidate to enter clinical development in 2008/early 2009.

"We are making great strides in developing potentially important therapeutics to address a wide range of cancer and inflammatory diseases," Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We continue to progress towards proof-of-concept for multiple programs and look forward to advancing our most promising candidates towards market approval."

Research and Development

Medarex has enhanced its core UltiMAb(R) antibody platform with a suite of technologies that optimize or enhance the therapeutic activity of antibodies. One important technology expansion is the company's proprietary antibody-drug conjugate (ADC) platform. Medarex believes that its ADC technology overcomes many of the key development challenges of drug conjugates, including issues of linker stability, potency and multi-drug resistance while maintaining a wide therapeutic window with minimal toxicity. Coupled with cutting-edge antibody technologies, Medarex's sophisticated drug development infrastructure and decision-making processes engage expertise in the areas of science, clinical development and market research to maximize efficiency, increase productivity, augment the quality of our antibody drug development eff
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
8. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
9. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Inferior Vena Cava (IVC) Filters - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... reach US$435 million by 2016. The North ... the global value while Europe ...
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... PLYMOUTH MEETING, Pa. , Dec. 15, 2014 ... ) announced today it has been added to ... the NASDAQ Biotechnology Index will become effective upon ... The NASDAQ Biotechnology Index is designed to track ... that are classified as either biotechnology or pharmaceutical ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
(Date:12/17/2014)... Unidesk Corporation today announced that ... welcomed its inaugural class in August 2013, has ... support bring your own device (BYOD) and deliver ... The solution, comprised of Citrix XenDesktop ... and storage infrastructure and Unidesk virtual ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... (HealthDay News) -- Expectant parents should leave prenatal picture-taking ... recommends. Use of ultrasound imaging and heartbeat monitors ... risk-free, the agency warns. "Although there is ... ultrasound imaging and heartbeat monitors, prudent use of these ... Vaezy, an FDA biomedical engineer, said in an agency ...
(Date:12/17/2014)... Kathleen Doheny HealthDay ... Chronic sleep loss is rampant in America, and work commitment ... is the No. 1 sleep killer," said Dr. Mathias Basner, ... the University of Pennsylvania Perelman School of Medicine. A ... older, found that work is the main activity exchanged for ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
Breaking Medicine News(10 mins):Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3
... HealthDay Reporter , TUESDAY, June 28 (HealthDay News) -- ... U.S. regulators, attention again Tuesday during a two-day hearing to ... the treatment of metastatic breast cancer. Back on Dec. ... of the drug to fight breast cancer, citing the ...
... University School of Medicine in St. Louis are performing ... irregular heartbeat. Available at only a handful of ... surgical techniques with the latest advances in catheter ablation, ... surface to block signals causing the heart to misfire. ...
... care nurses doubt that a clinical neurological examination can establish ... perceive that this uncertainty can affect relatives when the question ... from the Sahlgrenska Academy, University of Gothenburg, Sweden. ... caring for patients who are brain dead and who by ...
... with social interaction and attentiveness, and are also sensitive ... evident to parents during their child,s first two years, ... of Gothenburg. In her thesis, Dewrang investigated ... relative to their diagnosis. The thesis is based on ...
... mutations for two classes of p7 inhibitor, which may ... with current standard of care. Study results support the ... future HCV-specific therapies and are available in the July ... Wiley-Blackwell on behalf of the American Association for the ...
... regulated, as mistakes may lead to cancer. The so-called c-JUN ... and liver. The group of Veronika Sexl at the ... detail with the discovery an additional function of c-JUN,s also ... have recently been published in the open-access journal Oncotarget ...
Cached Medicine News:Health News:FDA to Hear Appeal on Breast Cancer Drug 2Health News:FDA to Hear Appeal on Breast Cancer Drug 3Health News:New procedure treats atrial fibrillation 2Health News:New procedure treats atrial fibrillation 3Health News:New procedure treats atrial fibrillation 4Health News:Intensive care nurses have doubts about method for establishing brain death 2Health News:Intensive care nurses have doubts about method for establishing brain death 3Health News:P7 protein resistance mutations identified; represent drug targets for hepatitis C virus 2Health News:The good, the bad and the ugly: The many roles of c-JUN in cancer 2
... operation for stent delivery. Uses perpendicular ... movement. Allows user to adjust stent ... Maintains tactile feel via fine adjustment ... in visualization at any angle. The ...
Vial with 100 Urine Reagent Test Strips, tests for glucose, protein, pH, blood, ketone, bilirubin, nitrite, urobilinogen, specific gravity. FOR LABORATORY USE BY QUALIFIED TECHNICIANS....
... the latest from Quality Mapping Solutions, ... designed specifically for implementing and managing ... superior design, functionality, security, and versatility ... managing a quality program., ,Based upon ...
... Q-Pulse is the UK's market-leading system ... 250 pathology laboratories in the UK ... In addition, hundreds of pathology laboratories ... South Africa and the United States ...
Medicine Products: